Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

The government may slash duties on imported rare disease and cancer drugs in the Union budget aiming to make lifesaving treatments affordable and ease financial burdens on patients ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

A new clinical trial, sponsored by UCL and UCLH, aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile ...

A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

According to Bladder Cancer UK, the main symptoms of bladder cancer are: ...